Literature DB >> 9671247

Gay men who engage repeatedly in unprotected anal intercourse with casual partners: the Sydney Men and Sexual Health Study.

P van de Ven1, D Campbell, S Kippax, S Knox, G Prestage, J Crawford, P Kinder, D Cooper.   

Abstract

We set out to determine the frequency and correlates of gay men's repeated unprotected anal intercourse with casual partners (UAI-C), defined as UAI-C reported at each of 3 annual interviews. By May 1997, 659 men had completed 3 annual interviews for the Sydney Men and Sexual Health (SMASH) cohort study. For the 3 6-month periods prior to each interview, 127 men reported UAI-C during one period only; 45 reported it during 2 periods; and 20 men reported it during all 3 periods. These 20 men who had repeated UAI-C were compared with 497 men who had anal intercourse with casual partners but did not report on all 3 occasions that they had UAI-C. Logistic regression revealed that repeated UAI-C was associated with HIV-positive status, more casual partners, less favourable attitudes toward condoms and greater recreational drug use. Few gay men have repeated UAI-C but those who do run greater risk of HIV transmission.

Entities:  

Mesh:

Year:  1998        PMID: 9671247     DOI: 10.1258/0956462981922368

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  An individually tailored intervention for HIV prevention: baseline data from the EXPLORE Study.

Authors:  Margaret A Chesney; Beryl A Koblin; Patrick J Barresi; Marla J Husnik; Connie L Celum; Grant Colfax; Kenneth Mayer; David McKirnan; Franklyn N Judson; Yijian Huang; Thomas J Coates
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

2.  Predictors of frequent use of amphetamine type stimulants among HIV-negative gay men in Sydney, Australia.

Authors:  Garrett Prestage; Louisa Degenhardt; Fengyi Jin; Andrew Grulich; John Imrie; John Kaldor; Susan Kippax
Journal:  Drug Alcohol Depend       Date:  2007-07-19       Impact factor: 4.492

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.